SofouGroup
Publications
Complete list of published work
Transport cocktails for cancer therapeutics
Kavousanakis M, Bhatavdekar O, Bastiaanet R, Kevrekidis Y, Sofou S.
Phys. Rev. Research 6, 033137 (2024)
https://doi.org/10.1103/PhysRevResearch.6.033137
Combined, yet Separate: cocktails of carriers (not drugs) for α-particle therapy of solid tumors expressing moderate-to-low levels of targetable markers
Nair R, Prasad A, Bhatavdekar O, Sarkar A, Gabrielson KL, Sofou S.
European Journal of Nuclear Medicine and Molecular Imaging 51, 2649–2662 (2024)
https://doi.org/10.1007/s00259-024-06710-0
Transport and Reaction Modeling of Nanocarriers for Cancer Therapeutics: Experimental and in silico approaches
Kavousanakis M, Bhatavdekar O, Sofou S, Kevrekidis I.
IFAC-PapersOnLine 55 (23), 104-108
https://doi.org/10.1016/j.ifacol.2023.01.023
The Rate of Cisplatin Dosing Affects the Resistance and Metastatic Potential of Triple Negative Breast Cancer Cells, Independent of Hypoxia
Bhatavdekar O, Godet I, Gilkes D, Sofou S.
Pharmaceutics. 2022 Oct 10. doi: 10.3390/pharmaceutics14102184. PMID: PMC9611288
https://pubmed.ncbi.nlm.nih.gov/36297617/
Predicting response of micrometastases with MIRDcell V3: proof of principle with 225Ac-DOTA encapsulating liposomes that produce different activity distributions in tumor spheroids.
Katugampola S, Wang J, Prasad A, Sofou S, Howell RW.
Eur J Nucl Med Mol Imaging. 2022 Jul 8. doi: 10.1007/s00259-022-05878-7. Online ahead of print.PMID: 35802160
https://pubmed.ncbi.nlm.nih.gov/35802160/
Two diverse carriers are better than one: a case study in α‐particle therapy for PSMA‐expressing prostate cancers
Salerno, D., Howe, A., Bhatavdekar, O., Josefsson, A., Pacheco‐Torres, J., Bhujwalla, Z.M., Gabrielson, K.L. and Sofou, S.,
Bioengineering & Translational Medicine, p.e10266.
https://aiche.onlinelibrary.wiley.com/doi/abs/10.1002/btm2.10266
Featured Basic Science Article: Combination of carriers, with complementary intratumoral microdistributions of delivered α-particles, may realize the promise for Actinium-225 in large solid tumors
Howe A, Bhatavdekar O, Salerno D, Josefsson A, Pacheco-Torres J, Bhujwalla ZM, Gabrielson KL, Sgouros G, Sofou S.
J Nucl Med. 2021 Nov 18:jnumed.121.262992. doi: 10.2967/jnumed.121.262992. Epub ahead of print.
PMID: 34795012.
https://pubmed.ncbi.nlm.nih.gov/34795012/
Growth Inhibition of Triple-Negative Breast Cancer: The Role of Spatiotemporal Delivery of Neoadjuvant Doxorubicin and Cisplatin
Dominick Salerno, Stavroula Sofou
Salerno D, Sofou S.
Pharmaceuticals (Basel). 2021 Oct 12;14(10):1035. doi: 10.3390/ph14101035.
PMID: 34681259
https://pubmed.ncbi.nlm.nih.gov/34681259/
Transport-driven engineering of liposomes for delivery of α-particle radiotherapy to solid tumors: effect on inhibition of tumor progression and onset delay of spontaneous metastases
Prasad A, Nair R, Bhatavdekar O, Howe A, Salerno D, Sempkowski M, Josefsson A, Pacheco-Torres J, Bhujwalla ZM, Gabrielson KL, Sgouros G, Sofou S.
Eur J Nucl Med Mol Imaging. 2021 Jun 12. doi: 10.1007/s00259-021-05406-z. Online ahead of print.
PMID: 34117896
https://pubmed.ncbi.nlm.nih.gov/34117896/
Daptomycin-Induced Lipid Phases on Model Lipid Bilayers: Effect of Lipid Type and of Lipid Leaflet Order on Membrane Permeability
Howe A, Sofou S.
J Phys Chem B. 2021 Jun 10;125(22):5775-5785. doi: 10.1021/acs.jpcb.1c02047. Epub 2021 May 26.
PMID: 34038100
https://pubmed.ncbi.nlm.nih.gov/34038100/
Growth of metastatic triple negative breast cancer is inhibited by deep tumor-penetrating and slow tumor-clearing chemotherapy: the case of tumor adhering liposomes with interstitial drug release.
Stras S, Howe A, Prasad A, Salerno D, Bhatavdekar O, Sofou S.
Mol Pharm. 2019 Dec 11. doi: 10.1021/acs.molpharmaceut.9b00812. Epub 2019 Dec 23.
PMID: 31825626
https://pubmed.ncbi.nlm.nih.gov/31825626/
Topical inhibition of PUMA signaling mitigates radiation injury.
Kowzun MJ, Rifkin WJ, Borab ZM, Ellison T, Soares MA, Wilson SC, Lotfi P, Bandekar A, Sofou S, Saadeh PB, Ceradini DJ.
Wound Repair Regen. 2018 Nov;26(6):413-425. doi: 10.1111/wrr.12668. Epub 2018 Oct 25.
PMID: 30155987
https://pubmed.ncbi.nlm.nih.gov/30155987/
Kinetic Analysis of Nanostructures Formed by Enzyme-Instructed Intracellular Assemblies against Cancer Cells.
Li J, Bullara D, Du X, He H, Sofou S, Kevrekidis IG, Epstein IR, Xu B.
ACS Nano. 2018 Apr 24;12(4):3804-3815. doi: 10.1021/acsnano.8b01016. Epub 2018 Mar 21.
PMID: 29537820
https://pubmed.ncbi.nlm.nih.gov/29537820/
Targeted and Nontargeted α-Particle Therapies
McDevitt MR, Sgouros G, Sofou S.
Annu Rev Biomed Eng. 2018 Jun 4;20:73-93. doi: 10.1146/annurev-bioeng-062117-120931. Epub 2018 Jan 18.
PMID: 29345977
https://pubmed.ncbi.nlm.nih.gov/29345977/
Clustered versus Uniform Display of GALA-Peptides on Carrier Nanoparticles: Enhancing the Permeation of Noncharged Fluid Lipid Membranes.
Locke T, Sofou S.
Langmuir. 2017 Nov 28;33(47):13625-13633. doi: 10.1021/acs.langmuir.7b03706. Epub 2017 Nov 13.
PMID: 29096061
https://pubmed.ncbi.nlm.nih.gov/29096061/
Alpha-particle radiotherapy: For large solid tumors diffusion trumps targeting
Zhu C, Sempkowski M, Holleran T, Linz T, Bertalan T, Josefsson A, Bruchertseifer F, Morgenstern A, Sofou S.
Biomaterials. 2017 Jun;130:67-75. doi: 10.1016/j.biomaterials.2017.03.035. Epub 2017 Mar 25.
PMID: 28365545
https://pubmed.ncbi.nlm.nih.gov/28365545/
Interstitial Release of Cisplatin from Triggerable Liposomes Enhances Efficacy against Triple Negative Breast Cancer Solid Tumor Analogues.
Stras S, Holleran T, Howe A, Sofou S.
Mol Pharm. 2016 Sep 6;13(9):3224-33. doi: 10.1021/acs.molpharmaceut.6b00439. Epub 2016 Aug 11.
PMID: 27482716
https://pubmed.ncbi.nlm.nih.gov/27482716/
Sticky Patches on Lipid Nanoparticles Enable the Selective Targeting and Killing of Untargetable Cancer Cells.
Sempkowski M, Zhu C, Menzenski MZ, Kevrekidis IG, Bruchertseifer F, Morgenstern A, Sofou S.
Langmuir. 2016 Aug 23;32(33):8329-38. doi: 10.1021/acs.langmuir.6b01464. Epub 2016 Aug 8.
PMID: 27468779
https://pubmed.ncbi.nlm.nih.gov/27468779/
Journal of Membrane Biology: Biotechnology and Engineering Section.
Sofou S, Borden M.
J Membr Biol. 2016 Apr;249(1-2):7. doi: 10.1007/s00232-016-9903-4.
PMID: 27090257
https://pubmed.ncbi.nlm.nih.gov/27090257/
Nanoconjugation of PSMA-Targeting Ligands Enhances Perinuclear Localization and Improves Efficacy of Delivered Alpha-Particle Emitters against Tumor Endothelial Analogues.
Zhu C, Bandekar A, Sempkowski M, Banerjee SR, Pomper MG, Bruchertseifer F, Morgenstern A, Sofou S.
Mol Cancer Ther. 2016 Jan;15(1):106-113. doi: 10.1158/1535-7163.MCT-15-0207. Epub 2015 Nov 19.
PMID: 26586724
https://pubmed.ncbi.nlm.nih.gov/26586724/
Phase separation behavior of mixed lipid systems at neutral and low pH: coarse-grained simulations with DMD/LIME.
Curtis EM, Xiao X, Sofou S, Hall CK.
Langmuir. 2015 Jan 27;31(3):1086-94. doi: 10.1021/la504082x. Epub 2015 Jan 15.
PMID: 25549801
https://pubmed.ncbi.nlm.nih.gov/25549801/
Liposome-based approaches for delivery of mainstream chemotherapeutics: preparation methods, liposome designs, therapeutic efficacy.
Sempkowski M, Locke T, Stras S, Zhu C, Sofou S.
Crit Rev Oncog. 2014;19(3-4):177-221. doi: 10.1615/critrevoncog.2014011533.
PMID: 25271431
https://pubmed.ncbi.nlm.nih.gov/25271431/
Time-restricted feeding and the realignment of biological rhythms: translational opportunities and challenges.
Sunderram J, Sofou S, Kamisoglu K, Karantza V, Androulakis IP.
J Transl Med. 2014 Mar 28;12:79. doi: 10.1186/1479-5876-12-79.
PMID: 24674294
https://pubmed.ncbi.nlm.nih.gov/24674294/
Anti-prostate-specific membrane antigen liposomes loaded with 225Ac for potential targeted antivascular α-particle therapy of cancer.
Bandekar A, Zhu C, Jindal R, Bruchertseifer F, Morgenstern A, Sofou S.
J Nucl Med. 2014 Jan;55(1):107-14. doi: 10.2967/jnumed.113.125476. Epub 2013 Dec 12.
PMID: 24337602
https://pubmed.ncbi.nlm.nih.gov/24337602/
Masking and triggered unmasking of targeting ligands on liposomal chemotherapy selectively suppress tumor growth in vivo
Bandekar A, Zhu C, Gomez A, Menzenski MZ, Sempkowski M, Sofou S.
Mol Pharm. 2013 Jan 7;10(1):152-60. doi: 10.1021/mp3002717. Epub 2012 Dec 18.
PMID: 23134440
https://pubmed.ncbi.nlm.nih.gov/23134440/
Antitumor efficacy following the intracellular and interstitial release of liposomal doxorubicin.
Bandekar A, Karve S, Chang MY, Mu Q, Rotolo J, Sofou S.
Biomaterials. 2012 Jun;33(17):4345-52. doi: 10.1016/j.biomaterials.2012.02.039. Epub 2012 Mar 17.
PMID: 22429980
https://pubmed.ncbi.nlm.nih.gov/22429980/
Floret-shaped solid domains on giant fluid lipid vesicles induced by pH.
Bandekar A, Sofou S.
Langmuir. 2012 Mar 6;28(9):4113-22. doi: 10.1021/la204765r. Epub 2012 Feb 22.
PMID: 22276950
https://pubmed.ncbi.nlm.nih.gov/22276950/
Nanocarriers to solid tumors: considerations on tumor penetration and exposure of tumor cells to therapeutic agents.
Bhagat M, Halligan S, Sofou S.
Curr Pharm Biotechnol. 2012 Jun;13(7):1306-16. doi: 10.2174/138920112800624256.
PMID: 22201591
https://pubmed.ncbi.nlm.nih.gov/22201591/
Heterogeneous liposome membranes with pH-triggered permeability enhance the in vitro antitumor activity of folate-receptor targeted liposomal doxorubicin.
Mamasheva E, O'Donnell C, Bandekar A, Sofou S.
Mol Pharm. 2011 Dec 5;8(6):2224-32. doi: 10.1021/mp200079y. Epub 2011 Sep 21.
PMID: 21899300
https://pubmed.ncbi.nlm.nih.gov/21899300/
The pH-dependent association with cancer cells of tunable functionalized lipid vesicles with encapsulated doxorubicin for high cell-kill selectivity.
Karve S, Bandekar A, Ali MR, Sofou S.
Biomaterials. 2010 May;31(15):4409-16. doi: 10.1016/j.biomaterials.2010.01.064. Epub 2010 Feb 26.
PMID: 20189243
https://pubmed.ncbi.nlm.nih.gov/20189243/
Large anti-HER2/neu liposomes for potential targeted intraperitoneal therapy of micrometastatic cancer
Sofou S, Enmon R, Palm S, Kappel B, Zanzonico P, McDevitt MR, Scheinberg DA, Sgouros G.
J Liposome Res. 2010 Dec;20(4):330-40. doi: 10.3109/08982100903544185. Epub 2010 Jan 13.
PMID: 20070139
https://pubmed.ncbi.nlm.nih.gov/20070139/
Membrane heterogeneities and fusogenicity in phosphatidylcholine-phosphatidic acid rigid vesicles as a function of pH and lipid chain mismatch
Bhagat M, Sofou S.
Langmuir. 2010 Feb 2;26(3):1666-73. doi: 10.1021/la9026283.
PMID: 19813725
https://pubmed.ncbi.nlm.nih.gov/19813725/
The use of pH-triggered leaky heterogeneities on rigid lipid bilayers to improve intracellular trafficking and therapeutic potential of targeted liposomal immunochemotherapy
Karve S, Alaouie A, Zhou Y, Rotolo J, Sofou S.
Biomaterials. 2009 Oct;30(30):6055-64. doi: 10.1016/j.biomaterials.2009.07.038. Epub 2009 Aug 7.
PMID: 19665223
https://pubmed.ncbi.nlm.nih.gov/19665223/
pH-dependent formation of lipid heterogeneities controls surface topography and binding reactivity in functionalized bilayers.
Kempegowda GB, Karve S, Bandekar A, Adhikari A, Khaimchayev T, Sofou S.
Langmuir. 2009 Jul 21;25(14):8144-51. doi: 10.1021/la9004032.
PMID: 19594187
https://pubmed.ncbi.nlm.nih.gov/19594187/
Frozen cyclohexane-in-water emulsion as a sacrificial template for the synthesis of multilayered polyelectrolyte microcapsules.
Khapli S, Kim JR, Montclare JK, Levicky R, Porfiri M, Sofou S.
Langmuir. 2009 Sep 1;25(17):9728-33. doi: 10.1021/la901020j.
PMID: 19507842
https://pubmed.ncbi.nlm.nih.gov/19507842/
Radionuclide carriers for targeting of cancer.
Sofou S.
Int J Nanomedicine. 2008;3(2):181-99. doi: 10.2147/ijn.s2736.
PMID: 18686778
https://pubmed.ncbi.nlm.nih.gov/18686778/